EP1239866A4 - Induzierung von zellulärer immunantwort auf her2/neu mit hilfe von peptid- und neukleinsäurezubereitungen - Google Patents

Induzierung von zellulärer immunantwort auf her2/neu mit hilfe von peptid- und neukleinsäurezubereitungen

Info

Publication number
EP1239866A4
EP1239866A4 EP00984214A EP00984214A EP1239866A4 EP 1239866 A4 EP1239866 A4 EP 1239866A4 EP 00984214 A EP00984214 A EP 00984214A EP 00984214 A EP00984214 A EP 00984214A EP 1239866 A4 EP1239866 A4 EP 1239866A4
Authority
EP
European Patent Office
Prior art keywords
neu
her2
peptide
nucleic acid
immune responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00984214A
Other languages
English (en)
French (fr)
Other versions
EP1239866A1 (de
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Robert Chesnut
Esteban Celis
Elissa Keogh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to EP05008363A priority Critical patent/EP1568373A3/de
Publication of EP1239866A1 publication Critical patent/EP1239866A1/de
Publication of EP1239866A4 publication Critical patent/EP1239866A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
EP00984214A 1999-12-10 2000-12-11 Induzierung von zellulärer immunantwort auf her2/neu mit hilfe von peptid- und neukleinsäurezubereitungen Withdrawn EP1239866A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05008363A EP1568373A3 (de) 1999-12-10 2000-12-11 Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45829999A 1999-12-10 1999-12-10
US458299 1999-12-10
PCT/US2000/033591 WO2001041787A1 (en) 1999-12-10 2000-12-11 INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05008363A Division EP1568373A3 (de) 1999-12-10 2000-12-11 Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen

Publications (2)

Publication Number Publication Date
EP1239866A1 EP1239866A1 (de) 2002-09-18
EP1239866A4 true EP1239866A4 (de) 2005-02-09

Family

ID=23820228

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00984214A Withdrawn EP1239866A4 (de) 1999-12-10 2000-12-11 Induzierung von zellulärer immunantwort auf her2/neu mit hilfe von peptid- und neukleinsäurezubereitungen
EP05008363A Withdrawn EP1568373A3 (de) 1999-12-10 2000-12-11 Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05008363A Withdrawn EP1568373A3 (de) 1999-12-10 2000-12-11 Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen

Country Status (5)

Country Link
EP (2) EP1239866A4 (de)
JP (1) JP2003530083A (de)
AU (1) AU2087401A (de)
CA (1) CA2393738A1 (de)
WO (1) WO2001041787A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515192A (ja) 2001-11-29 2005-05-26 ダンドリット バイオテック アクティーゼルスカブ ヒト又は動物において免疫応答を誘導するための医薬組成物
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
AU2003292127A1 (en) * 2002-11-26 2004-06-18 Antarus Lifescience Gmbh Method for the generation of antibodies against a desired antigen using preselected animals for immunization
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
CA2514288C (en) * 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
AU2004232971A1 (en) 2003-04-18 2004-11-04 Idm Pharma Inc. HLA-A2 tumor associated antigen peptides and compositions
JPWO2005007694A1 (ja) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
EP1682159A4 (de) 2003-10-16 2010-07-21 Stephen John Ralph Immunomodulierende zusammensetzungen und ihre verwendungen
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20080171058A1 (en) * 2003-11-13 2008-07-17 Polly Gregor Compositions and Methods For Synergistic Induction of Antitumor Immunity
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP4961706B2 (ja) * 2004-09-29 2012-06-27 東レ株式会社 Ｈｌａクラスｉｉ拘束性新規癌抗原ペプチド
CN101370513B (zh) * 2005-12-23 2013-04-03 瓦克松生物技术公司 由肿瘤抗原衍生的优化隐蔽性肽组成的免疫原性多肽及其用途
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US20100310640A1 (en) * 2007-11-01 2010-12-09 Knutson Keith L Hla-dr binding peptides and their uses
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EA024730B1 (ru) 2010-04-15 2016-10-31 Медимьюн Лимитед Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов
KR101839163B1 (ko) 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
AU2011338281A1 (en) 2010-12-08 2013-07-11 Expression Pathology, Inc. Truncated Her2 SRM/MRM assay
EP2655401B1 (de) * 2010-12-20 2016-03-09 The Regents of the University of Michigan Hemmer der bindeinteraktion des epidermalen wachstumsfaktor-rezeptor-wärmeschock-proteins 90
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
EP2755677B1 (de) * 2011-09-15 2020-11-04 Medigene AG Anti-her2-impfstoff auf der basis von multimeren strukturen aus aav
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
AU2013221309B2 (en) * 2012-02-17 2017-03-30 Mayo Foundation For Medical Education And Research Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
LT2839860T (lt) 2012-10-12 2019-07-10 Medimmune Limited Pirolobenzodiazepinai ir jų konjugatai
HUE042731T2 (hu) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
TR201815418T4 (tr) 2012-10-12 2018-11-21 Adc Therapeutics Sa Pirrolobenzodiazepin -anti-psma antikor konjugatları.
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP2906296B1 (de) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
EP2906251B1 (de) 2012-10-12 2017-09-27 ADC Therapeutics SA Pyrrolobenzodiazepin-anti-cd22-antikörperkonjugate
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EP2935268B2 (de) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazepine und konjugate davon
RU2014102939A (ru) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для чрескожного введения
RU2014102941A (ru) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
US9821074B2 (en) 2013-03-13 2017-11-21 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
TWI636792B (zh) 2013-08-12 2018-10-01 建南德克公司 １－（氯甲基）－２，３－二氫－１ｈ－苯并［ｅ］吲哚二聚體抗體－藥物結合物化合物及使用與治療方法
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
CN107106700B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191521A2 (de) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cystein-manipulierte antikörper und konjugate
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3235820A1 (de) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazepine und antikörper-disulfid-konjugate davon
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
US10537576B2 (en) 2015-12-09 2020-01-21 Expression Pathology, Inc. Methods for treating Her2-positive breast cancer
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
MA44605A (fr) * 2016-04-06 2019-02-13 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
EP3465221B1 (de) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
EP3496763A1 (de) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
LT3544636T (lt) 2017-02-08 2021-06-25 Adc Therapeutics Sa Pirolobenzodiazepino-antikūno konjugatai
EP3612537B1 (de) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepinkonjugate
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
MX2020001880A (es) 2017-08-18 2021-07-06 Medimmune Ltd Conjugados de pirrolobenzodiazepina.
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. ANALOGUES OF THAILANSTATINE
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (de) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Konjugierte chemische abbauauslöser und verwendungsverfahren
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
FR3119325B1 (fr) 2021-01-29 2023-08-11 Renault Jean Yves Compositions liposomales orales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
EP1189624A4 (de) * 1999-06-29 2005-02-23 Epimmune Inc Hla-bindende peptide und deren verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISK BRYAN ET AL: "Identification of an Immunodominant Peptide of HER-2/neu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 181, no. 6, 1995, pages 2109 - 2117, XP009030958, ISSN: 0022-1007 *
KONO KOJI ET AL: "Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes", INTERNATIONAL JOURNAL OF CANCER, vol. 78, no. 2, 5 October 1998 (1998-10-05), pages 202 - 208, XP002280379, ISSN: 0020-7136 *
See also references of WO0141787A1 *

Also Published As

Publication number Publication date
WO2001041787A1 (en) 2001-06-14
JP2003530083A (ja) 2003-10-14
CA2393738A1 (en) 2001-06-14
EP1568373A2 (de) 2005-08-31
EP1568373A3 (de) 2005-12-21
EP1239866A1 (de) 2002-09-18
AU2087401A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
EP1239866A4 (de) Induzierung von zellulärer immunantwort auf her2/neu mit hilfe von peptid- und neukleinsäurezubereitungen
EP1244465A4 (de) Induzierung von zellulärer immunantwort gegen prostatakrebsantigenen mittels peptid- und nukleinsäureverbindungen
EP1225907A4 (de) Induktion zellulärer immunantworten gegen humanes immundefiziens virus-1 (hiv-1) mittels peptid- und nukleinsäureverbindungen
AU6226100A (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1732598A4 (de) Auslösung von zellulären immunantworten gegen den humanen papillovirus unter verwendung von peptid und nucleinsäure-zusammensetzungen
AU7828100A (en) Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
IL195649A0 (en) Compositions comprising anti-??v??3 recombinant human antibodies and nucleic acids encoding the same
PL356297A1 (en) Recombinant antibodies to human interkleukin-1 beta
AU4835001A (en) Antibodies to human cd154
EP1254666A4 (de) Stabile antikörper zusammensetzungen und injektions formulierungen
IL120902A0 (en) Interferon conjugates their preparation and pharmaceutical compositions containing them
HUP0103085A3 (en) Formulations an processes for inducing an immune response to polysaccharide
HUP0203325A3 (en) Bicyclic amino acids, pharmaceutical compositions containing them and their use
EP0977494A4 (de) Essbare zusammensetzung enthaltend ein teilchenförmiges gel
EP1165586A4 (de) Tcl-1b gene und proteine und verwandte methoden und verfahren
EP1235848A4 (de) Anregung cullärer immun-antworten zu einem carcinoembryonen antigen unter verwendung von peptiden und nuklein-säure-zusammensetzungen
IL143027A0 (en) Generation of antibodies using polynucleotide vaccination in avian species
EP1293204A4 (de) Urea-enthaltende gelzusammensetzung
IL130608A0 (en) Novel nucleic and amino acid sequence
EP1235841A4 (de) Induzierung von zellulärer immunantwort auf mage2/3 mit hilfe von peptid- und nukleinsäurezubereitungen
EP1237564A4 (de) Induktion zellulärer immunantworten gegen p53 mittels peptid und nukleinsäure-verbindungen
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
IL158293A (en) Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same
EP1064354A4 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FÜR AUD GENEN BASIERENDE VAKZINE ZUM HERVORRUFEN VON T-Zell ANTWORTEN
PL362867A1 (en) Human heparanase-related polypeptide and nucleic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CELIS, ESTEBAN

Inventor name: SIDNEY, JOHN

Inventor name: KEOGH, ELISSA

Inventor name: SETTE, ALESSANDRO

Inventor name: CHESNUT, ROBERT

Inventor name: FIKES, JOHN

Inventor name: SOUTHWOOD, SCOTT

A4 Supplementary search report drawn up and despatched

Effective date: 20041227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050315

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHESNUT, ROBERT

Inventor name: SETTE, ALESSANDRO

Inventor name: CELIS, ESTEBAN

Inventor name: SIDNEY, JOHN

Inventor name: KEOGH, ELISSA

Inventor name: SOUTHWOOD, SCOTT

Inventor name: FIKES, JOHN